Arcturus Therapeutics Holdings Inc. (ARCT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '21: 8.8M Q4 '21: 12.4M Q1 '22: 15.5M Q2 '22: 40.6M Q3 '22: 51.5M Q4 '22: 206M Q1 '23: 281M Q2 '23: 264.5M Q3 '23: 296.2M Q4 '23: 166.8M Q1 '24: 124.5M Q2 '24: 163.9M Q3 '24: 160.4M Q4 '24: 152.3M Q1 '25: 143.7M Q2 '25: 122.1M Q3 '25: 97.6M Q4 '25: 82M Q1 '26: 54.7M Q2 '26: 29.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -196.3M Q4 '21: -202.9M Q1 '22: -195.6M Q2 '22: -163.9M Q3 '22: -146.9M Q4 '22: 12.2M Q1 '23: 77.3M Q2 '23: 44M Q3 '23: 61.5M Q4 '23: -78.2M Q1 '24: -123.4M Q2 '24: -89.1M Q3 '24: -80.5M Q4 '24: -95.7M Q1 '25: -82.1M Q2 '25: -72.6M Q3 '25: -78.3M Q4 '25: -76.3M Q1 '26: -88.4M Q2 '26: -102.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -196.1M Q4 '21: -203.7M Q1 '22: -198.5M Q2 '22: -165.5M Q3 '22: -146.7M Q4 '22: 9.3M Q1 '23: 111.3M Q2 '23: 80.3M Q3 '23: 99.3M Q4 '23: -29.7M Q1 '24: -107.3M Q2 '24: -72M Q3 '24: -62.6M Q4 '24: -80.9M Q1 '25: -68.2M Q2 '25: -60.2M Q3 '25: -66.7M Q4 '25: -65.8M Q1 '26: -78.7M Q2 '26: -93.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -99.2M Q4 '21: -135M Q1 '22: -141.1M Q2 '22: -145M Q3 '22: -170.8M Q4 '22: 32M Q1 '23: 45.2M Q2 '23: 132.8M Q3 '23: 142.8M Q4 '23: -18.1M Q1 '24: 12.2M Q2 '24: -68.7M Q3 '24: -60.1M Q4 '24: -59.7M Q1 '25: -89.3M Q2 '25: -64.9M Q3 '25: -58.3M Q4 '25: -74.3M Q1 '26: -58.6M Q2 '26: -72.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -102.2M Q4 '21: -138.4M Q1 '22: -146.5M Q2 '22: -149.6M Q3 '22: -175.8M Q4 '22: 24.3M Q1 '23: 38.9M Q2 '23: 125.8M Q3 '23: 137M Q4 '23: -21M Q1 '24: 9.8M Q2 '24: -71.2M Q3 '24: -61.6M Q4 '24: -60.4M Q1 '25: -89.9M Q2 '25: -65.2M Q3 '25: -58.6M Q4 '25: -74.5M Q1 '26: -58.7M Q2 '26: -72.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 10M 20M 30M Q2 '21: 26.3M Q3 '21: 26.3M Q1 '22: 26.4K Q2 '22: 26.4K Q3 '22: 26.5K Q1 '23: 27.1M Q2 '23: 26.6M Q3 '23: 26.6M Q1 '24: 26.9M Q2 '24: 27M Q3 '24: 27.1M Q1 '25: 27.1M Q2 '25: 27.1M Q3 '25: 27.2M Q1 '26: 28.4M Q2 '26: 28.4M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q1 '20: -2.06 Q2 '20: -2.54 Q3 '20: -2.90 Q4 '20: -3.39 Q1 '21: -4.87 Q2 '21: -6.39 Q3 '21: -7.52 Q4 '21: -7.74 Q3 '23: 3.72 Q4 '23: -1.12 Q1 '24: -3.99 Q2 '24: -2.65 Q3 '24: -2.30 Q4 '24: -3.01 Q1 '25: -2.53 Q2 '25: -2.23 Q3 '25: -2.46 Q4 '25: -2.40 Q1 '26: -2.83 Q2 '26: -3.33 Q2 '20 Q1 '21 Q4 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.